Yonsei University
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1123 trials with phase data)• Click on a phase to view related trials
Development and Effectiveness Verification of an AI Application for Pressure Injury Nursing Based on Clinical Judgment Model
- Conditions
- Pressure UlcerNursing Education
- Interventions
- Biological: Pressure Ulcer Nursing AI Application TrainingBiological: Traditional Pressure Ulcer Nursing Education
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 95
- Registration Number
- NCT07132320
- Locations
- 🇰🇷
Severance Hospital, Wound Ostomy Team, Seoul, Korea, Republic of
Ultrasonic Versus Conventional Clipping Hemostasis in Laparoscopic Colorectal Surgery
- Conditions
- Adenocarcinoma of the Colon
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 304
- Registration Number
- NCT07129512
- Locations
- 🇰🇷
Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of
Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure
- Conditions
- Atrial FibrillationAtrial FlutterTachycardia, SupraventricularHeart Septal Defects, Atrial
- Interventions
- Drug: Beta-blocker treatment groupDrug: Non-treatment group
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 350
- Registration Number
- NCT07123506
- Locations
- 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Application-Based Integrated Care in Patients After Pulse Field Ablation
- Conditions
- Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 500
- Registration Number
- NCT07119528
- Locations
- 🇰🇷
Division of Cardiology Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
- Conditions
- Diabetes Mellitus, Type 2HyperglycemiaInsulin Resistance
- Interventions
- Drug: Sitagliptin 100 mg + Dapagliflozin 10 mgDrug: Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 100
- Registration Number
- NCT07108985
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 267
- Next